Company
Rocket Pharmaceuticals
Rocket Pharmaceuticals has 7 drugs tracked on RxWires: 3 in Phase 2, 1 in Phase 1/2, 3 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| RP-L301 | Phase 2 | Pyruvate Kinase Deficiency |
| RP-L102 | Phase 2 | Fanconi Anemia Complementation Group A |
| RP-A501 | Phase 2 | Danon Disease |
| RP-L201 | Phase 1/2 | Leukocyte Adhesion Defect - Type I |
| RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3) | Phase 1 | Dilated Cardiomyopathy (DCM) |
| RP-A601 | Phase 1 | PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) |
| RP-L401 | Phase 1 | Infantile Malignant Osteopetrosis |
Latest
- rocket pharmaceuticals filed 8-K
- rocket pharmaceuticals filed 8-K
- rocket pharmaceuticals filed 8-K
- rocket pharmaceuticals filed 8-K
- rocket pharmaceuticals filed 8-K
Follow Rocket Pharmaceuticals on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.